Table 5 Selected first-line phase 3 trials in ALK rearranged NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
ALEX | NCT02075840 | Alectinib vs crizotinib | 82.9 vs 75.5 | 34.8 vs 10.9 (HR 0.43) | NR vs NR (HR 0.76) |
ALTA-1L | NCT02737501 | Brigatinib vs crizotinib | 74 vs 62 | 24.0 vs 11.1 (HR 0.48) | NR vs NR (HR 0.81) |
CROWN | NCT03052608 | Lorlatinib vs crizotinib | 77 vs 59 | NR vs 9.3 (HR 0.28) | NR vs NR |